AXIM Biotech Holds Bi-Annual Board Meeting in New York City on July 8

NEW YORK, July 12, 2017 (GLOBE NEWSWIRE) — AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, announced today that it held its bi-annual board meeting on July 8, 2017 in New York City. AXIM Biotech board members reviewed company milestones for the first half of 2017, clinical trial progress for irritable bowel syndrome (IBS), multiple sclerosis (MS) and psoriasis and eczema (PSO), the Company’s expanding product portfolio, and the current market opportunity for cannabinoid-based pharmaceuticals.   

Management and advisory board experts considered further proof of concept studies of cannabis based treatment for indications such as nicotine addiction, Glaucoma, dry eye syndrome, adolescent drug addiction, post-haerpetic neuralgia, traumatic brain injury (TBI), and ethyl alcohol abuse. Other items discussed during the board meeting included AXIM’s collaborations with leading academic institutions, strategic relationships with big-pharma

... read more at:

Leave a Reply

Your email address will not be published. Required fields are marked *